They Said “2–3 Months to Live” — 10 Years Later, He's Thriving | Dr. Dino Prato

This episode explores challenging medical prognoses, from inoperable tumors to dire timelines, highlighting the critical need for advanced patient care.

Dr. Prato discusses how precise oncology approaches can offer hope, even when traditional healthcare options seem limited. By focusing on personalized cancer treatment, we aim to redefine what's possible for every cancer patient.

🎯 What You’ll Learn in This Episode:

• What “2–3 months to live” typically means clinically
• Why cancer varies between patients
• The role of deeper biological testing
• What multi-omics analysis includes
• Why monitoring between scans matters
• The concept of immune-focused treatment strategies
• 5 key questions to ask your doctor
• How treatment planning may evolve over time

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“When cancer is complex, decisions should be guided by deeper data — not just timelines.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493

Transcript

SPEAKER_00 0:08

A surgeon stopped mid-operation, not because the patient couldn't handle it, because the tumor was wrapped around what they couldn't touch. Another patient was told you have about two to three months to live. That was in 2014. And a young woman with stage four breast cancer spread to the liver and bone was told it was only manageable at best. That's the words doctors use with these families. Today I'm going to show you how those were turned around. And by the end of the video, you will see the three steps and the five questions that can change every treatment decision you or someone you love ever makes because you need to know this before someone you love is told there's nothing left that can be done. There's a difference between cancer and your cancer, and the difference changes outcomes. So stay with me. We're gonna go through these five cases and I'm gonna show you how they got turned around. I'm Dr. Dino Prado, founder of InVita Medical Centers. For the last 25 years, my team and I have helped patients who have failed to top hospitals across the country using precision and targeted care. So we don't use guesswork. We use immune-centric care and precision oncology, which has made all the difference, deep testing and targeted treatment strategies. And today I'm gonna show you how this has worked for these complex cancer cases and many others that we help. When we stop treating cancer like a category and start treating it like a biological fingerprint, we see an immense difference. Make sure you're working with a doctor before you change anything. So let's get started and get right into this. I've watched terminal cases turn around, and the pattern is almost always the same. Three steps. Step one, finally do the deep testing, multi-omics. Not just a scan, not just biopsies, not just tumor markers, but I'm talking about full understanding of DNA, RNA, and full understanding of immune spatial biology and immune profiling. You're not just looking for one mutation. We're mapping everything out. We can do this through blood tests, and we can do it through information from the tumor because guessing is not only expensive, but it can cost somebody's life. And guessing wastes time. So step two, you want to treat the biology, not the panic. The standard of care panic says, we found your cancer, we need to treat you right away, and they hit hard. Precision says, hold on, let's get all the information and now we're gonna hit smarter. Sometimes it's the metronomic, fractionated microdosing that works better because it's immune-centric or direct to tumor that works better because it creates an immune reaction at the tumor, like a vaccine that's custom for each patient. It's these types of targeted agents and planning and delivery that makes all the difference. And immune-centric care that also is metabolic, diet and lifestyle changes, root cause analysis become really important. Then, step three, monitor and adapt. Because understanding how the cancer treatment is working before you wait for imaging and tumor markers is so important. You want to look at leading indicators, circulating tumor cells, methylation scores. These give you so much more information. And you'll understand the biology that's whispering the response is working or not, months before you see the tumor grow. This gives you an advantage. So you don't wait for pictures and just track basic signals. You look for detailed planning. So let's look at these five stories. Let's move right into them. Stay with me to the end because on case five, it'll change the way you think about statistics. Number one, this is one of the most difficult cancers to treat, pancreatic cancer. Statistically, one of the hardest. Five-year survival data on this is not very good. But this patient did fantastically well at a very aggressive chemotherapy regimen, chemo radiation, and then came out of surgery and the surgeon stopped. The tumor was wrapped into critical structures. It was inoperable. So the next message was we're just gonna do more chemotherapy. But she had already paid the price. She had neuropathy, toxicity, quality of life was collapsing. And she said, basically, I'm paraphrasing her, I'm not gonna do this again. I'd rather die. Just to be clear, sometimes treatment can get so bad and so difficult that a patient's done. That's not denial. That's just the reality of cancer when it gets into late stage cases. That's a patient demanding a smarter plan, wanting help. So she came and we built it for her through precision. Her immune suppression, inflammation, metabolic strain, tumor markers, all the multi-omics deep planning, immune programs. And then we used a strategic approach. We didn't need all the toxicity. We could go much lower in microdose with multi-agents because we knew which ones to use. We paired it with the right immunotherapy, rebuilding the body's immune system. And here's the key. We didn't hope, we measured. Now, over time, we saw stable imaging and improvements, and molecular markers were doing fantastic. But the key to the outcome was you need to know that each patient was different because two pancreatic cancers with the same type and stage, you're gonna have a totally different response. So we saw no evidence of disease after imaging. We got rid of it by the grace of God. She transitioned into what we call support and home care, where our team continues to work, and the patient did fantastically well for a long time. So she was told she was gonna die, and now she's alive. So precision oncology was fantastic in this case. And we still use those same maneuvers today with every patient. That's a pancreatic cancer case. Let me move to another one. I'm picking difficult ones. Now we do this for breast and colon and prostate and all different cancer types, but I'm focusing on difficult, difficult cases that standard of care oncology basically send you home to hospice. Second case, which is a very advanced head and neck cancer, we made the invisible visible. It's an HPV associated head and neck cancer. Standard of care did radiation, it did all of its work and chemo, but with no avail. But he asked a question that I think a lot of patients need to ask what are the right targets for me? How will I know if the cancer is going to come back and if the treatment is working? And we need to find a better plan. So we did that. Deep multiomics testing, right targeting, immune-centric care with deep profiling, and we were able to treat them and look at reoccurrence in a very detailed way. So we weren't flying blind after therapy. We could monitor remission holding and holding, and we found the patient didn't have to deal with the radiation of taste loss, dry mouths, mucosal pain, anxiety that he did before. We were able to treat it with immunotherapy direct. And that was the turning point. We did post-treatment surveillance and it was negative and the disease stayed away. No circulating tumor cell signals, no pain and suffering that he had with his previous treatment. Now the patient's been in remission for many years, but it's not just remission, it's the idea that the body has the ability to heal itself if we give it what it needs. It's the proof of our body's biology that's been intelligently designed by God to heal. And if we can build an immune system where the body can recognize a cancer, it makes a huge difference. That's precision oncology. It's not just about killing cancer, it's about teaching the body to fight cancer and hold remission. Sometimes it's about removing some of those mental blocks where we're being told there's nothing else that can be done and getting the right testing and getting all the options in front of us and letting our body do the work. So if you're tracking me, we're moving on to case three. And this is where most people miss the real game. So pay attention to this case because this is something that a lot of people don't get. If you believe the patients deserve better than just treating like statistics, then subscribe because that's exactly what this channel was built for. And almost 90% of the people watching right now aren't subscribed. So help us get precision oncology out there. If this helps just one person, one family member, it's all worth the time to educate and help. Ask better questions with your doctor. Understand your options. It's all worth it. All right, let me move into the case here. So in this case three, we had a late-stage metastatic breast cancer, very advanced. Reoccurrence came back. So remember, the risk of breast cancer returning can be like 30% for certain types of breast cancers without the strategic follow-up that I'm going to go into here. This patient was proactive. They found the lesion, they confirmed the malignancy, and they tried to move fast and they went and built a plan. Radiation, chemo, didn't work. Radiation, chemo. So then she came to us and we built a precision plan immediately that was immunotherapy-centric. One of the things you'll see with breast cancer is there's very little effective immunotherapy. But with what we do, everything is immune-centric because we custom build it. Full molecular mapping, immune and inflammation marker, circulating tumor cells, all of the RNA, DNA, doing all the work we do, and then direct to tumor. And here's the part that most people miss. The key to survivorship, like we see in this case with long-term remission with a very difficult breast cancer, was because the immune system was front and center. And here's the question: how do we keep the biology quiet for years through immunity? Because we have to build a long-term architecture that's structured on immune surveillance, a precise treatment that not only focuses on metabolic, we know diet lifestyle, metabolic, gut microbiome immunity. We're talking about directed tumor, immune stability and monitoring and treatment, because the immune system is our first and last events against cancer. And this patient was missing that. Not random follow-up appointments, but targeted understanding of the immune system and how to treat it. That's what helped this cancer go into remission and not come back. A living, breathing strategy that a patient can have, a custom-built plan for them. So years later, still in remission, doing fantastic, reassuring that the surveillance is there and the patient, as they move more and more into remission, one year, two years, three years, with a disease that at first seemed incurable is now in remission for many years. So the precision done right with immune planning makes all the difference. It protects the patient's treatment now and the future. And that's what makes all the difference. This is what every patient deserves to overcome these difficult cancers. Another breast cancer case, stage four, again, very advanced, just like the previous one I talked about. This one was triple positive with metastases to the liver and bone. And now she's thriving. But she was estrogen positive, progesterone positive, and HERC2 positive. Metastases confirmed it to the liver and the bone. But a lot of those hormone treatments are not the key to holding remission. They buy you time. The key was targeting it with immunotherapy because she had metastases, very advanced metastases to the liver and the bone. And at some point, the medications that block hormones stopped working because they're just buying time. So what we were able to do is pair it with targeted immunotherapy after deep mapping. And then we were able to measure months that turned into years and holding long-term remission because the key was we cleaned up the toxicity, got rid of the root causes, and re-established the immune system. See, that's proper planning. It wasn't just random integrative care or random conventional care. It was targeted to her specific map. So the plan was perfect to her biology and her response, years and years of remission. We've used these combined strategies over and over again with many cancer types, many types, breast, prostate, colon, lung, you name it. Precision systems work because they're designed on the individual person. It's not just giving a HERC to drug that buys you time, her septin or something, but it's about using the right immunotherapy in the right target for the patient. And the immunotherapies are custom built. That's the key. And I believe as we go into the future, it's the immunotherapy drugs that are going to change the world of cancer. The response for her was strong, markers improved. We did adaptive monitoring, looked at leading, not just lagging indicators, pushing her into remission. Months turned into years and years and years. And now you have a patient who doesn't panic about cancer, didn't have to worry as a lot. So that's the power of precision oncology. And so you can see these cases when you go to our website. We have so many testimonials. You can watch these patients. That's not just managing a disease, that's eliminating it. That's rebuilding somebody's immune system and their life. So now let me get to case five. So listen closely because remember, I mentioned case five before. Before I give you this last case, I want you to know something. The oncologist who reviewed this patient's outcome, a physician at a major institution, was not only surprised, they were shocked. Not because of the medicine that we used that was magic, but the techniques. And that made all the difference was a strategy. This is case number five. A patient that had two to three months to live, a metastatic picture that didn't fit neatly into any protocol. And he was told at these major cancer hospitals, if I mentioned it, you'd know them right away. They only had two to three months to live. Now I don't buy that. I think everybody's time to live is based by the grace of God. And when we get into testing, those things can change. But that's what standard of care gave. So now listen, standard oncology is built on pattern recognition. One size fits all. Everybody gets the same thing for the same type and stage of cancer. You fail one regimen, go into the other regimen. But when you get these advanced metastatic cancers, it's very hard to see because in these very late-stage cancers, typically you have less than a 5% true five-year survival. That's what you have in these very difficult cancers. But this person wasn't a statistic, and you're not either. When you have deep testing, you don't have to become a statistic. So we approached it going after the immune system to tackle this cancer, a plan designed to restore that body's anti-tumor surveillance. And now focusing on monitoring and targeting immunotherapy, those two to three months turned into long-term remission, many years of remission. And if that doesn't wake us up, nothing else will. So this particular cancer was a colon cancer sent home to die and had turned around. That's the power testing, the power of targeting. A cold tumor turned hot. And that's really, really important. So let me be completely honest with you. Precision oncology does not guarantee everybody heals from late-stage cancer, but it tremendously improves the quality and length of life in our clinical experience. Cancer is complex, but if you have the right testing and the right ability to build custom targets and care, you can greatly improve patient outcomes, particularly with immunotherapy. So here's what I'm saying: when you treat cancer like a generic enemy or one size fits all, you're going to get the same responses. But when you can get precision targeting and you can get after the immune system, immune evasion, resistant pathways, metabolic drivers, causative agents with deep testing, targeted care, now you can get to the next level. And sometimes patients never get this far because they don't have this option. And my goal is to improve that education and help people to realize that there are other tools, other testing that can help them. You can often live longer with a better quality of life, fewer toxicity. Some of the patients we treat literally are hiking and exercising during treatment because of the microdosing and targeting that we use. So that's what changes the world when I think of precision oncology. People don't have to suffer and they don't have to guess. They can get out of dogma and get into data. So let me leave you with these three steps. Okay, so you can see there was a pattern in all these patients. Number one, they finally got deep testing and they knew what made their tumor tick. And they knew what was going on in their immune system and finally corrected it. So they didn't just stop at here's an X regimen, here's another scan. They wanted more information. Step two, they treated the blueprint for themselves. So the treatment plan was immune-centric directly for each patient's unique markers. Not panicking, but hitting smarter, not harder, because the key was rebuilding the immune system. And finally, step three was adaptive monitoring. So we knew if the patient was responding way before the tumor would reappear. This is how you get long-term responses. Now I've seen it over the years with all kinds of cancers. I can name almost every cancer type we've treated over 25, 27 years that has had an amazing response, but it's based on their targets and each patient is different. So these are the questions that I want you to think about when you talk to your doctor. What deep testing have we done beyond basic pathology? Question number two, are we tracking minimal residual disease or molecular signals between scans? Question number three, are we doing something for my immune system to get my T cells involved to go after the tumor? Question four, what's the plan to reduce inflammation, infection, metabolic drivers that are causing the cancer? Question number five, if this stops working, what's my next plan? What's the targeting? How are you going to adapt to treatment? And what data are you using to make that happen? If the answer to that is we don't know, we don't understand, I think you need a new doctor. That's the difference when you think precision oncology. That's how you stop being a number and start getting targeting. It doesn't mean that by using precision oncology, the cancer is automatically in remission, but you have a huge advantage because now you have the right targets. So just like these cases we've seen that are almost like resurrection cases, late stage, very advanced diseases, you would see them. They would be just like you would imagine a late-stage cancer patient in a hospital sent home to die that are turned around. The key is you need the right testing and targeting to give the body the best chance for healing. So I hope you like these strategies because it's really about testing, targeting, and strategy. And that's how we want to change oncology. Please share this with someone you know. Get the information out there on precision oncology. Subscribe, help the channel to get out there so more people can learn about precision, not just become a statistic and the one size fits all. I hope you found this episode helpful and may the Lord bless you on your journey to healing.